Dimeric IgA specifically disables intracellular mutated oncodrivers

A prevailing belief in the immunotherapy field has been that antibody therapy can effectively target only extra -cellular antigens. In this issue of Immunity, Biswas et al. demonstrate therapeutically effective targeting, neutralization, and removal of mutated oncodriver proteins from within epithelial cancer cells by treatment with pIgR-dependent, transcytosing dimeric-IgA antibodies.